|Bid||0.00 x 1100|
|Ask||0.00 x 900|
|Day's Range||60.13 - 61.63|
|52 Week Range||42.67 - 80.00|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||18.16|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal fossa) and saphenous (in adductor canal) nerve blocks in patients after lower extremity surgeries. The trial did not meet the primary endpoint of statistical significance in pain reduction from 0 to 96 hours for Exparel versus bupivacaine HCl. Exparel did achieve statistical significance versus bupivacaine HCl for secondary endpoints of reducing cumulative pain scores from 24 to 96 hours post-surgery and total opioid consumption from 24 to 96 hours post-surgery. The Exparel group achieved and maintained mild pain at 36 hours while bupivacaine HCl was in the moderate range. There were no clinically relevant safety issues observed in the study, specifically no reports of falls and no serious adverse events observed in the study. Pacira plans to submit the full results from the study for presentation at future scientific conferences and publication in a peer-reviewed journal. Price Action: PCRX shares are down 2.17% at $64.96 during the premarket session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaOraSure Resubmits EUA Applications for ELISA COVID-19 Antibody TestProgenity's Targeted Delivery Of Adalimumab Shows Encouraging Action In Animal Models Induced With Colitis© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.